An assessment of mismatch repair deficiency in ovarian tumours at a public hospital in Johannesburg, South Africa
Main Article Content
Abstract
Background. Epithelial ovarian carcinomas (EOCs) are lethal female genital tract malignancies with high-grade serous, low-grade serous, endometrioid, clear cell, mucinous and malignant Brenner subtypes. The lifetime risk for developing ovarian carcinoma (OC) is 15% in females who have mismatch repair deficiency (MMR-d). MMR-d is associated with Lynch syndrome, a cancer predisposition condition. Patients who have MMR-d may benefit from immunotherapy. To the best of the authors’ knowledge, MMR-d testing of OCs in South Africa (SA) has not been undertaken to date.
Objectives. To assess the clinicopathological characteristics and mismatch repair (MMR) status of non-serous EOCs at a single institution in SA.
Methods. Following ethical clearance and application of exclusion criteria, 19 cases of non-serous EOC from the Department of Anatomical Pathology at Charlotte Maxeke Johannesburg Academic Hospital were retrieved and assessed. Four immunohistochemical markers (MLH1, MSH2, MSH6 and PMS2) were used to evaluate MMR status.
Results. Most tumours were early-stage, unilateral, mucinous EOCs, without capsular breach or lymphovascular invasion (LVI). A single case of grade 1, stage I, unilateral, endometrioid EOC showed MMR-d for MLH1 and PMS2 MMR proteins. This patient had been diagnosed with endometrioid endometrial carcinoma 2 years prior to the diagnosis of OC.
Conclusion. Our study documented a lower proportion of MMR-d OCs compared with international studies. However, our results are concordant with global studies regarding tumour subtype, laterality, grade, stage, LVI and capsular breach. Larger studies are required to estimate the true incidence of MMR-d OCs in SA and to direct effective treatment options globally.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The SAJOG is published under an Attribution-Non Commercial International Creative Commons Attribution (CC-BY-NC 4.0) License. Under this license, authors agree to make articles available to users, without permission or fees, for any lawful, non-commercial purpose. Users may read, copy, or re-use published content as long as the author and original place of publication are properly cited.
Exceptions to this license model is allowed for UKRI and research funded by organisations requiring that research be published open-access without embargo, under a CC-BY licence. As per the journals archiving policy, authors are permitted to self-archive the author-accepted manuscript (AAM) in a repository.
How to Cite
References
Ferlay J, Ervik M, Lam F, et al. Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer, 2020. http://gco.iarc.fr/today/ (accessed 4 May 2021).
South African National Cancer Registry, National Health Laboratory Service. Summary statistics of cancer diagnosed histologically in 2017: Female – all population groups combined. National Institute for Communicable Diseases, 2018. https://www.nicd.ac.za/wp-content/uploads/2020/12/ NCR_2017_Final_02dec2020.pdf (accessed 13 May 2021).
Reid BM, Permuth JB, Sellers TA. Epidemiology of ovarian cancer: A review. Cancer Biol Med 2017;14(1):9-32. https://doi.org/10.20892/j.issn.2095-3941.2016.0084
Seidman J. Advances in sub-classification of ovarian carcinomas by cell type: An update. Diagn Histopathol 2014;20(9):351-356. https://doi.org/10.1016/j.mpdhp.2014.07.005
Prat J; FIGO Committee on Gynecologic Oncology. Staging classification for cancer of the ovary, fallopian tube, and peritoneum. Int J Gynecol Obstet 2014;124(1):1-5. https://doi.org/10.1016/j. ijgo.2013.10.001
Chui MH, Gilks CB, Cooper K, Clarke BA. Identifying Lynch syndrome in patients with ovarian carcinoma: The significance of tumor subtype. Adv Anat Pathol 2013;20(6):378-386. https://doi. org/10.1097/pap.0b013e3182a92cf8
Strafford JC. Genetic testing for Lynch syndrome, an inherited cancer of the bowel, endometrium, and ovary. Rev Obstet Gynecol 2012;5(1):42-49.
Pal T, Permuth-Wey J, Sellers TA. A review of the clinical relevance of mismatch-repair deficiency in ovarian cancer. Cancer 2008;113(4):733-742. https://doi.org/10.1002/cncr.23601
Richman S. Deficient mismatch repair: Read all about it (Review). Int J Oncol 2015;47(4):1189-202. https://doi.org/10.3892/ijo.2015.3119
Wadee R, Grayson W. A potpourri of pathogenetic pathways in endometrial carcinoma with a focus on Lynch syndrome. Ann Diagn Pathol 2019;39:92-104. https://doi.org/10.1016/j. anndiagpath.2019.02.003
BarrowE,HillJ,EvansDG.CancerriskinLynchsyndrome.FamCancer2013;12(2):229-240.https:// doi.org/10.1007/s10689-013-9615-1
Lee V, Murphy A, Le DT, Diaz LA. Mismatch repair deficiency and response to immune checkpoint blockade. Oncologist 2016;21(10):1200-1211. https://doi.org/10.1634/theoncologist.2016-0046
HaunschildCE,TewariKS.Thecurrentlandscapeofmolecularprofilinginthetreatmentofepithelial ovarian cancer. Gynecol Oncol 2021;160(1):333-345. https://doi.org/10.1016/j.ygyno.2020.09.043
Torina TB, Hudspeth EL, Chun JM, Zaloga W, Alderink C, Abdeen Y. An unusual occurrence of
multiple metachronous and synchronous primary cancers in a female patient. Case Rep Oncol Med
;2020:5691732. https://doi.org/10.1155/2020/5691732
Grindedal EM, Renkonen-Sinisalo L, Vasen H, et al. Survival in women with MMR mutations and
ovarian cancer: A multicentre study in Lynch syndrome kindreds. J Med Genet 2010;47(2):99-102.
https://doi.org/10.1136/jmg.2009.068130
Backes FJ, Cohn DE. Lynch syndrome. Clin Obstet Gynecol 2011;54(2):199-214. https://doi.
org/10.1097/GRF.0b013e3182185a41
Leskela S, Romero I, Cristobal E, et al. Mismatch repair deficiency in ovarian carcinoma:
Frequency, causes, and consequences. Am J Surg Pathol 2020;44(5):649-656. https://doi.org/10.1097/
pas.0000000000001432
Romero I, Bast RC. Minireview: Human ovarian cancer: Biology, current management, and paths to
personalizing therapy. Endocrinology 2012;153(4):1593-1602. https://doi.org/10.1210/en.2011-2123
Shahsiah R, Salarvand S, Miri R, Ghalehtaki R, Rakhshani N. The prevalence and associated factors of microsatellite instability in ovarian epithelial cancers detected by molecular genetic studies in a sample of Iranian women. Int J Cancer Manag 2017;10(12):e11599. https://doi.org/10.5812/
ijcm.11599
Murphy MA, Wentzensen N. Frequency of mismatch repair deficiency in ovarian cancer: A
systematic review: This article is a US Government work and, as such, is in the public domain of the United States of America. Int J Cancer 2011;129(8):1914-1922. https://doi.org/10.1002/ijc.25835
Lokadasan R, James FV, Naranayan G, Prabhakaran PK. Targeted agents in epithelial ovarian cancer: Review on emerging therapies and future developments. Ecancermedicalscience 2016;10:626. https:// doi.org/10.3332/ecancer.2016.626
Lheureux S, Braunstein M, Oza AM. Epithelial ovarian cancer: Evolution of management in the era of precision medicine. CA Cancer J Clin 2019;69(4):280-304. https://doi.org/10.3322/caac.21559
Zhu J, Ke G, Bi R, Wu X. Clinicopathological and survival characteristic of mismatch repair status
in ovarian clear cell carcinoma. J Surg Oncol 2020;122(3):538-546. https://doi.org/10.1002/jso.25965 24. Lobandji A. Antigen retrieval on formalin-fixed paraffin-embedded tissue. Standard Operating Procedure, document no. ANA0008, version 3. Johannesburg: National Health Laboratory Service,
active 23 January 2017, last review 18 January 2019.
Lobandji A. Immunohistochemistry – standard protocol for making adhesive slides. Standard
Operating Procedure, document no. ANA0005, version 1. Johannesburg: National Health Laboratory
Service, active 24 March 2006, last review 18 January 2019.
Lobandji A. Making antibody dilutions. Standard Operating Procedure, document no. ANA0590,
version 1. Johannesburg: National Health Laboratory Service, active 22 May 2008, last review 30
April 2019.
Lobandji A. Optimisation of primary antibodies. Standard Operating Procedure, document no.
ANA0010, version 1. Johannesburg: National Health Laboratory Service, active 24 March 2006, last
review 18 January 2019.
World Health Organization Classification of Tumours Editorial Board. Female Genital Tumours.
WHO Classification of Tumours Series, 5th ed., vol. 4. Lyon, France: International Agency for
Research on Cancer, 2020. https://publications.iarc.fr/592 (accessed 4 May 2021).
Akbari MR, Zhang S, Cragun D, et al. Correlation between germline mutations in MMR genes and microsatellite instability in ovarian cancer specimens. Fam Cancer 2017;16(3):351-355. https://doi.
org/10.1007/s10689-017-9973-1
Tajima Y, Eguchi H, Chika N, et al. Prevalence and molecular characteristics of defective mismatch
repair epithelial ovarian cancer in a Japanese hospital-based population. Jpn J Clin Oncol
;48(8):728-735. https://doi.org/10.1093/jjco/hyy081
Lee J-H, Cragun D, Thompson Z, et al. Association between IHC and MSI testing to identify
mismatch repair-deficient patients with ovarian cancer. Genet Test Mol Biomarkers 2014;18(4):229-
https://doi.org/10.1089/gtmb.2013.0393
Peres LC, Cushing-Haugen KL, Köbel M, et al. Invasive epithelial ovarian cancer survival by histotype
and disease stage. J Natl Cancer Inst 2019;111(1):60-68. https://doi.org/10.1093/jnci/djy071
Matsuo K, Yoshino K, Hiramatsu K, et al. Effect of lymphovascular space invasion on survival of stage I epithelial ovarian cancer. Obstet Gynecol 2014;123(5):957-965. https://doi.org/10.1097/
aog.0000000000000240
Matsuo K, Machida H, Yamagami W, et al. Intraoperative capsule rupture, postoperative
chemotherapy, and survival of women with stage I epithelial ovarian cancer. Obstet Gynecol
;134(5):1017-1026. https://doi.org/10.1097/AOG.0000000000003507
Garg S, Kaur A, Mohi JK, Sibia PK, Kaur N. Evaluation of IOTA simple ultrasound rules to
distinguish benign and malignant ovarian tumours. J Clin Diagn Res 2017;11(8):TC06-TC09. https://
doi.org/10.1097/10.7860/JCDR/2017/26790.10353
Lheureux S, Gourley C, Vergote I, Oza AM. Epithelial ovarian cancer. Lancet 2019;393(10177):1240-
https://doi.org/10.1016/S0140-6736(18)32552-2
PratJ.Newinsightsintoovariancancerpathology.AnnOncol2012;23(Suppl10):x111-x117.https://
doi.org/10.1093/annonc/mds300
Busca A, Nofech‐Mozes S, Olkhov‐Mitsel E, et al. Histological grading of ovarian mucinous
carcinoma – an outcome‐based analysis of traditional and novel systems. Histopathology
;77(1):26-34. https://doi.org/10.1111/his.14039
Vang R, Shih I-M, Kurman RJ. Ovarian low-grade and high-grade serous carcinoma: Pathogenesis,
clinicopathologic and molecular biologic features, and diagnostic problems. Adv Anat Pathol
;16(5):267-282. https://doi.org/10.1097/pap.0b013e3181b4fffa
Ryan NAJ, Evans DG, Green K, Crosbie EJ. Pathological features and clinical behavior of Lynch
syndrome-associated ovarian cancer. Gynecol Oncol 2017;144(3):491-495. https://doi.org/10.1016/j.
ygyno.2017.01.005
Fraune C, Rosebrock J, Simon R, et al. High homogeneity of MMR deficiency in ovarian cancer.
Gynecol Oncol 2020;156(3):669-675. https://doi.org/10.1016/j.ygyno.2019.12.031
HodanR,KinghamK,CotterK,etal.PrevalenceofLynchsyndromeinwomenwithmismatchrepair‐
deficient ovarian cancer. Cancer Med 2021;10(3):1012-1017. https://doi.org/10.1002/cam4.3688
Crosbie EJ, Ryan NAJ, McVey RJ, et al. Assessment of mismatch repair deficiency in ovarian cancer. J
Med Genet 2021;58(10):687-691. https://doi.org/10.1136/jmedgenet-2020-107270
Nakamura K, Banno K, Yanokura M, et al. Features of ovarian cancer in Lynch syndrome (Review).
Mol Clin Oncol 2014;2(6):909-9016. https://doi.org/10.3892/mco.2014.397
Kim SR, Tone A, Kim RH, et al. Performance characteristics of screening strategies to identify Lynch syndrome in women with ovarian cancer. Cancer 2020;126(22):4886-4894. https://doi.org/10.1002/
cncr.33144